New Delhi: India's pharmaceutical sector is poised for a stronger dose of revenue growth at 11-13 per cent this fiscal year compared to 8 per cent a year earlier, driven by accelerating exports and firmer domestic demand, according to a report by Crisil Ratings.
However, this higher revenue growth is unlikely to flow through fully to earnings as cost inflation in raw materials, energy, and freight is expected to compress operating margins by 150-200 basis points (bps) to 21-21.5 per cent, the rating agency said.
